Two and a half years after Wegovy’s original 2.4 mg dose redefined obesity treatment, Novo Nordisk just raised its own bar. On March 19, 2026, the FDA approved Wegovy HD — semaglutide 7.2 mg, more than triple the original approved dose — for adults with obesity who have already tolerated 2.4 mg for at least four weeks and need additional weight reduction. It is, by Novo Nordisk’s own framing, the highest weight loss ever recorded for a Wegovy injection, and it arrived through the same accelerated FDA pathway that fast-tracked Lilly’s oral orforglipron weeks earlier.
What Changed
Wegovy HD isn’t a new drug — it’s a higher dose of the same semaglutide molecule already approved as Wegovy 2.4 mg, Ozempic, and Rybelsus. What’s new is the ceiling. Patients who plateau on the standard 2.4 mg dose, or whose clinicians judge that more weight loss is clinically warranted, now have an FDA-sanctioned path to titrate up rather than switch products entirely. The approval also folds into Wegovy’s existing label, which already includes a reduced cardiovascular risk indication for adults with established heart disease — meaning Wegovy now covers a wider span of the treatment ladder than any single competing product.
The approval moved unusually fast: the FDA granted Wegovy HD a Commissioner’s National Priority Voucher, the same accelerated pilot program that fast-tracked Foundayo (orforglipron) into approval this spring. Two obesity drugs from two competing manufacturers clearing the FDA through the same expedited door in the same quarter is itself a signal — regulators are treating meaningful advances in obesity pharmacology as a national health priority, not a routine incremental filing.
Inside the STEP UP Trial
The approval rests on STEP UP, a 72-week, randomized, placebo- and active-controlled Phase 3b trial that enrolled 1,407 adults with obesity (BMI of 30 or higher) who did not have diabetes, comparing once-weekly semaglutide 7.2 mg against both placebo and the standard 2.4 mg dose. The results, later published in The Lancet Diabetes & Endocrinology, were the largest average weight loss yet reported in a Wegovy trial.
Participants who stayed on 7.2 mg for the full 72 weeks lost an average of roughly 21% of body weight; looking at everyone regardless of adherence, the number was closer to 19%. About one in three patients on the high dose — 31.2% — lost a quarter or more of their body weight, compared with 15.3% on standard-dose Wegovy and effectively none on placebo. For context, average starting body weight in the trial was around 248 to 257 pounds, meaning many participants lost 50 pounds or more.
Those numbers put Wegovy HD in the same performance tier as tirzepatide‘s higher doses, closing a gap that had opened between Novo Nordisk’s flagship product and Eli Lilly’s dual-agonist competitor. It’s a meaningful defensive move in a category where efficacy differences of even a few percentage points shape prescribing habits and market share.
The Trade-Off: More Weight Loss, More Side Effects
Higher doses of any GLP-1 tend to come with a higher side-effect burden, and Wegovy HD is no exception. Gastrointestinal effects tracked with the rest of the semaglutide class, but one symptom stood out in the trial data: dysesthesia, an altered or abnormal skin-sensation symptom, showed up in 22% of patients on 7.2 mg, compared to about 6% on standard-dose Wegovy and roughly 0.3% on placebo. That’s a large enough jump that clinicians will likely watch for it specifically when titrating patients upward, and it’s a reminder that “higher dose, more results” isn’t a free upgrade — it’s a different risk-benefit calculation that has to be made with a prescriber, not a spreadsheet.
What a Physician Actually Said About It
W. Timothy Garvey, MD, director of the Diabetes Research Center at the University of Alabama at Birmingham and one of the investigators on the STEP UP program, said the new dose “could reshape healthcare professionals’ expectations about what outcomes are possible” for patients on Wegovy. That’s a notable statement from a clinical researcher, not a marketing department — it reflects a real shift in how obesity medicine specialists are recalibrating what a “successful” outcome on a GLP-1 looks like, now that 20%-plus average weight loss is achievable with an injectable that’s already widely covered and distributed.
Availability and Cost
Novo Nordisk rolled out Wegovy HD in April 2026 through the same distribution network as the rest of the Wegovy line — more than 70,000 U.S. pharmacies including CVS and Costco, select telehealth providers, NovoCare Pharmacy, and GoodRx. Through NovoCare’s self-pay savings offer, Wegovy HD runs $399 for a one-month supply (one box of four pens), with a limited-time two-fill offer available through the end of 2026 for eligible patients. As with every GLP-1 on the market, actual out-of-pocket cost depends heavily on insurance coverage, employer formularies, and whether a patient qualifies for manufacturer savings programs — the sticker price and the real price are rarely the same number.
Frequently Asked Questions
Is Wegovy HD a different drug from regular Wegovy?
No. It’s the same active ingredient, semaglutide, at a higher 7.2 mg weekly dose rather than the original 2.4 mg maximum. Think of it as a new rung on an existing ladder, not a new drug.
Can anyone start on Wegovy HD?
No. The approval specifically covers patients who have already tolerated the 2.4 mg dose for at least four weeks and whose clinician determines additional weight reduction is appropriate. It is a step-up option, not a starting dose.
How does it compare to tirzepatide (Zepbound) or retatrutide?
At roughly 19–21% average weight loss, Wegovy HD now sits close to tirzepatide’s higher-dose results and within range of early retatrutide data, though cross-trial comparisons should be read with caution since study populations and protocols differ. For a deeper look at how the multi-receptor drugs stack up, see our breakdown of retatrutide’s triple-agonist mechanism and our comparison of Ozempic and Wegovy dosing.
Is this related to Foundayo (orforglipron)?
Only in timing and regulatory pathway. Foundayo is a different molecule entirely — a non-peptide oral pill from Eli Lilly — that was approved through the same National Priority Voucher program earlier in 2026. Read more in our coverage of the Foundayo approval.
What are the main risks of the higher dose?
The standard GLP-1 warnings apply (thyroid C-cell tumor risk, pancreatitis, gallbladder issues, GI symptoms), plus a notably higher rate of dysesthesia — abnormal skin sensations — at 22% versus 6% on the standard dose. Anyone titrating up should discuss this specific risk with their prescriber.
The Bigger Picture
Wegovy HD doesn’t change the fundamental chemistry of semaglutide, but it does change the competitive math. Novo Nordisk now has a dose that can credibly compete with tirzepatide on raw efficacy numbers, using a molecule that’s been on the market — and covered by insurers — for years longer than its rivals. Combined with Foundayo’s oral convenience play and the ongoing retatrutide trials, 2026 is shaping up as the year GLP-1 therapy stopped being a single-drug story and became a genuine multi-front competition, with real consequences for what patients can access and what it costs them.
This article is for educational purposes only and summarizes publicly available FDA and manufacturer information. It is not medical advice. Wegovy HD is a prescription medication available only through a licensed healthcare provider — talk to your doctor about whether dose escalation is appropriate for you.